These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 2443815)

  • 1. The effect of biological response modifiers on chronic and latent murine cytomegalovirus infections.
    Okada M; Minamishima Y
    Microbiol Immunol; 1987; 31(5):435-47. PubMed ID: 2443815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effect of biological response modifiers on murine cytomegalovirus infection.
    Ebihara K; Minamishima Y
    J Virol; 1984 Jul; 51(1):117-22. PubMed ID: 6202880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of biological response modifiers against murine cytomegalovirus infection in normal and immunodeficient mice.
    Okada M; Minamishima Y
    Microbiol Immunol; 1987; 31(1):45-57. PubMed ID: 3035349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inability of interferon to protect virus-infected cells against lysis by natural killer (NK) cells correlates with NK cell-mediated antiviral effects in vivo.
    Bukowski JF; Welsh RM
    J Immunol; 1985 Nov; 135(5):3537-41. PubMed ID: 2413125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Chlorella vulgaris extracts on murine cytomegalovirus infections.
    Ibusuki K; Minamishima Y
    Nat Immun Cell Growth Regul; 1990; 9(2):121-8. PubMed ID: 1693753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of immunosuppression with cyclophosphamide on acute murine cytomegalovirus infection and virus-augmented natural killer cell activity.
    Selgrade MK; Daniels MJ; Hu PC; Miller FJ; Graham JA
    Infect Immun; 1982 Dec; 38(3):1046-55. PubMed ID: 6295940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis of murine cytomegalovirus infection in natural killer cell-depleted mice.
    Bukowski JF; Woda BA; Welsh RM
    J Virol; 1984 Oct; 52(1):119-28. PubMed ID: 6207307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular reactivation of MCMV after immunosuppression of latently infected BALB/c mice.
    Zhang M; Xin H; Duan Y; Atherton SS
    Invest Ophthalmol Vis Sci; 2005 Jan; 46(1):252-8. PubMed ID: 15623781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of murine cytomegalovirus disease does not prevent latent virus infection.
    Katzenstein DA; Crane RT; Jordan MC
    J Lab Clin Med; 1986 Aug; 108(2):155-60. PubMed ID: 3016127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 9-(1-3-Dihydroxy-2-propoxymethyl)guanine prevents death but not immunity in murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice.
    Wilson EJ; Medearis DN; Hansen LA; Rubin RH
    Antimicrob Agents Chemother; 1987 Jul; 31(7):1017-20. PubMed ID: 2821884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of NK cells in immunomodulator-mediated resistance to herpesvirus infection.
    Kunder SC; Wu L; Morahan PS
    Antiviral Res; 1993 Jun; 21(2):103-18. PubMed ID: 8393316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine cytomegalovirus-induced suppression of antigen-specific cytotoxic T lymphocyte maturation.
    Campbell AE; Slater JS; Futch WS
    Virology; 1989 Nov; 173(1):268-75. PubMed ID: 2554572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a retroviral immunodeficiency syndrome on resistance to MCMV: a role for natural killer cells.
    Peacock CD; Price P
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct; 10(2):120-8. PubMed ID: 7552475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effect of MDP-Lys(L18), a synthetic derivative of muramyldipeptide, on murine cytomegalovirus infection.
    Eizuru Y; Nakagawa N; Hamasuna R; Minamishima Y
    Nat Immun; 1992; 11(4):225-36. PubMed ID: 1384831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host-mediated antiviral activity of Lactobacillus casei against cytomegalovirus infection in mice.
    Ohashi T; Yoshida A; Minamishima Y
    Biotherapy; 1988; 1(1):27-39. PubMed ID: 2484431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EBI3 regulates the NK cell response to mouse cytomegalovirus infection.
    Jensen H; Chen SY; Folkersen L; Nolan GP; Lanier LL
    Proc Natl Acad Sci U S A; 2017 Feb; 114(7):1625-1630. PubMed ID: 28143936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of NK cell activity in age-dependent resistance of mice to murine cytomegalovirus infection.
    Hayashi K; Eizuru Y; Sato S; Minamishima Y
    Microbiol Immunol; 1985; 29(10):939-50. PubMed ID: 3001484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aging and reactivation of latent murine cytomegalovirus.
    Schmader KE; Rahija R; Porter KR; Daley G; Hamilton JD
    J Infect Dis; 1992 Dec; 166(6):1403-7. PubMed ID: 1331252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VIPhyb, an antagonist of vasoactive intestinal peptide receptor, enhances cellular antiviral immunity in murine cytomegalovirus infected mice.
    Li JM; Darlak KA; Southerland L; Hossain MS; Jaye DL; Josephson CD; Rosenthal H; Waller EK
    PLoS One; 2013; 8(5):e63381. PubMed ID: 23723978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural cytotoxicity of murine cytomegalovirus-infected cells mediated by mouse lymphoid cells: role of interferon in the endogenous natural cytotoxicity reaction.
    Lee GD; Keller R
    Infect Immun; 1982 Jan; 35(1):5-12. PubMed ID: 6172385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.